Alper Gürlek

Alper Gürlek

Auto-generated profile, based on publicly available information

Alper Gürlek

25Division of Endocrinology and Metabolic Diseases, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkiye

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Journal of Atherosclerosis and Thrombosis
Verified
Journal Article
Open access
KGKadri Murat Gurses
Kadri Murat Gurses
LTLale TOKGÖZOĞLU
Lale TOKGÖZOĞLU
MYMuhammed Ulvi Yalçın Yalçın
Muhammed Ulvi Yalçın Yalçın
DKDuygu Kocyigit
Duygu Kocyigit
BEBanu Evranos
Banu Evranos
KAKudret Aytemir
Kudret Aytemir
Vitamin D deficiency, which is prevalent among young women in Middle Eastern populations, has been linked to cardiovascular disease. Epicardial adipose tissue (EAT) has also been found to be associated with coronary artery disease. However, data on the relationship between vitamin D status and epicardial adiposity is limited. This study aims to investigate the effect of vitamin D deficiency and replacement therapy on EAT thickness in healthy, young premenopausal women. Thirty-one premenopausal women with vitamin D deficiency and 31 age-matched women with normal vitamin D levels were enrolled in this study. EAT thickness was measured echocardiographically. Measurements were performed at baseline in both groups and were repeated at the 6-month follow-up in vitamin D deficient subjects after vitamin D replacement therapy. The baseline plasma 25-hydroxyvitamin D levels were lower in the vitamin D deficient group compared to the control group and were significantly improved following replacement therapy. EAT thickness was significantly higher in the vitamin D deficient group, and no significant change occurred following replacement therapy. In the linear regression analysis, waist circumference (β=0.031 [0.005-0.057], p=0.020) and 25(OH)D level (β=-0.020 [(-0.028)-(-0.013)], p<0.001) independently correlated with EAT thickness. Vitamin D deficiency is associated with a significant increase in EAT thickness in premenopausal women; however, a net beneficial response to adequate replacement therapy was not observed during the short period of therapy during our study. Longer periods of replacement therapy and follow-up may be useful to demonstrate the potential beneficial effects of vitamin D replacement on epicardial adiposity.

1 July 2021 in European Journal of Rheumatology
Verified
Journal Article
Open access
FSFulden Saraç
Fulden Saraç
AGAlper Gürlek
Alper Gürlek
ASAlev Selek
Alev Selek
ODOğuzhan Deyneli
Oğuzhan Deyneli
EAErsin Akarsu
Ersin Akarsu
SSsemra aytürk salt
semra aytürk salt
Objective: Paget disease of bone (PDB) is a metabolic bone disease that has been rarely reported in the Eastern countries. This study aimed to evaluate the clinical and demographic characteristics of patients with PDB followed up at endocrinology clinics in Turkey. Methods: An invitation was sent to tertiary endocrinology clinics to complete a survey on the demographic, clinical, radiological, and laboratory parameters, as well as treatment modalities of patients with PDB. This study enrolled clinically and radiologically proven 185 patients with PDB from 18 endocrinology centers based in 10 cities of Turkey. Results: This cohort of PDB had female preponderance (women/men: 105/80) with a mean age, during diagnosis, of 57±10 years. Most of the patients (59.6%) were symptomatic at diagnosis. Bone pain and headache were the predominant clinical symptoms. Polyostotic disease was observed in 67.5% (n=125) of patients. Frequently affected bones were skull (41.6%), pelvis (53.5%), spine (41%), and femur (25.4%). Moreover, 17 patients with skull involvement had hearing loss. Mean serum alkaline phosphatase (ALP) level (552±652 IU/L; range: 280-5762 IU/L) was over the normal reference cutoff with normal serum calcium levels. Intravenous bisphosphonates (zoledronic acid, 5 mg; pamidronate, 60-90 mg) were the most used drugs (75%) for the treatment of PDB. Most of the patients (87.1%) treated with intravenous bisphosphonates responded well, with a decrease in serum ALP level (117±114 IU/L) in the 12th month of therapy. Furthermore, 16 patients relapsed after the second year of therapy; 3 patients did not respond to the initial intravenous bisphosphonate treatment. Conclusion: The patients with PDB followed up by endocrinology clinics of Turkey exhibited polyostotic disease with classical clinical, radiological, and biochemical features and women’s predominance with good response to intravenous bisphosphonate therapy. Cite this article as: Gogas Yavuz D, Aytürk S, Çetinkalp Ş, Bayraktar F, Kulaksızoğlu M, Hekimsoy Z, et al. Clinical and demographic aspects of Paget disease of bone: A multicentric study from Turkey. Eur J Rheumatol 2021; 8(3): 156-61.

12 December 2025 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
PDF file
ACAsena GÖKÇAY CANPOLAT
Asena GÖKÇAY CANPOLAT
KAKemal Ağbaht
Kemal Ağbaht
AEAtilla Halil Elhan
Atilla Halil Elhan
MCMustafa Cesur
Mustafa Cesur
ZUZiynet Alphan Uc
Ziynet Alphan Uc
MSMustafa - Sahin
Mustafa - Sahin
Background/aim: To describe Graves’ Disease (GD) associated with COVID-19 infection (COVID) or its vaccines (VAC) and to compare the clinical presentations, laboratory parameters, and short-term clinical course of the disease among different etiology groups (COVID, VAC, and GD control). Materials and methods: Included in this multicenter matched case–control, retrospective cohort study were 239 patients with newly diagnosed (n = 196) or recurrent GD (n = 43) associated with COVID (n = 79) or VAC (n = 160). Each case was matched (1:1) with a control who had been diagnosed with GD prior to COVID. Results: The median age of the entire group was 42 years (female:male = 137:102). Both the COVID (4.6-fold) and VAC (4.1-fold) groups demonstrated higher TSH receptor antibody (TRAb) titers (p < 0.001) compared with the control group (3.5-fold), as well as a higher proportion of recurrent cases. At baseline, the COVID group had higher free triiodothyronine (fT3) levels than the other groups. Graves orbitopathy (GO) was observed in 60 patients (12.6%), with a higher frequency in classical GD (18.4%). At baseline, the variables associated with thyrotoxicosis severity (defined as fT3 levels) were younger age, higher thyroid gland volume (TGV), and etiology, with the COVID and, to a lesser extent, VAC groups presenting with higher fT3 levels. The variables associated with GO were higher TGV, TRAb titers, and smoking, while no association with etiology was identified. Conclusion: The clinical course was similar in all groups other than in some laboratory findings. Although the frequency of GO associated with COVID and VAC was lower, the proportion of cases with a Clinical Activity Score of ≥3 was higher compared to GD. This pattern suggests a potentially stronger immunologic trigger in these cases.

14 October 2025 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
PDF file
STSeli̇n Teki̇n
Seli̇n Teki̇n
NBNergi̇s Basmaci
Nergi̇s Basmaci
ILİnCi̇lAy Lay
İnCi̇lAy Lay
AGAlper Gürlek
Alper Gürlek
Background/aim: This study aimed to evaluate the metabolic profile of adults with Down syndrome (DS) using novel anthropometric and metabolic indices, while also highlighting the limitations of traditional obesity assessment methods compared with the non-DS population. Materials and methods: This cross-sectional study included 22 adults with DS and 28 age- and sex-matched non-DS controls. Anthropometric measurements, including BMI, waist circumference (WC), and hip circumference (HC), were recorded alongside novel indices such as waist-to-height ratio (WHtR), body adiposity index (BAI), A body shape index (ABSI), and visceral adiposity index (VAI). Metabolic parameters (fasting plasma glucose, HbA1c, lipid profiles, HOMA-IR) and CBC-derived inflammation indices (NLR, PLR, MHR, NHR, LHR, PHR, SII, AISI, SIRI) were evaluated. Results: Despite comparable BMI, individuals with DS exhibited significantly higher WHtR and BAI values (p < 0.001), suggesting greater central adiposity. Interestingly, the prevalence of metabolic syndrome was lower in the DS group (9.1%), and diastolic blood pressure was significantly lower as well. WHtR and BAI demonstrated stronger associations with metabolic markers than BMI. Among inflammatory indices, PLR was uniquely elevated in individuals with DS (p = 0.038), while VAI showed strong correlations with both. Conclusion: Adults with DS display distinct cardiometabolic profiles that are poorly captured by traditional indices. Novel markers such as WHtR, BAI, and VAI offer enhanced insight into metabolic risk, whereas PLR emerges as a potential inflammatory biomarker. These findings underscore the need for population- and sex-specific criteria in evaluating metabolic health in DS. Tailored diagnostic models may improve risk stratification and clinical outcomes for this vulnerable group.

27 December 2023 in Acta Medica
Verified
Journal Article
Open access
PDF file
GKGulnar Kazimzade
Gulnar Kazimzade
OKOlcay Kurtulan
Olcay Kurtulan
AAAytekin Akyol
Aytekin Akyol
SBSinem Bakır
Sinem Bakır
JKJale Karakaya
Jale Karakaya
AGAlper Gürlek
Alper Gürlek
Objective: This study investigated the role of pigment epithelium-derived factor (PEDF), vascular endothelial growth factor (VEGF), nuclear factor kappa B (NF-kB), and Ki-67 proliferation index (PI) factors in Medullary thyroid carcinoma (MTC) tissue progression and their relationship with tumor angiogenesis. Immunohistochemical (IHC) analyses of PEDF expression in various human tumor samples and healthy tissues have shown that high levels of PEDF expression are associated with a positive prognosis, and low levels of PEDF suggest a poorer prognosis. With the completion of further studies showing the antitumor effects of PEDF on different types of cancer, PEDF’s potential as a therapeutic agent has become increasingly promising. To the best of our knowledge, the role of PEDF in tumor angiogenesis in MTC has not been previously investigated. Material and Methods: Thirty-seven tissue samples were retrospectively analyzed and sent/removed for pathology after total or subtotal thyroidectomy and archived between 01.01.2000 and 31.12.2015 in the Pathology Department of Hacettepe University. Relationships between categorical variables are analyzed using Pearson Chi-squared or Fisher’s Exact tests.The correlation between two numerical variables is analyzed using Spearman’s Rho correlation coefficient, and a comparison of numerical variables between two groups is made using the Mann-Whitney U test. Results: The clinicopathological features of the patients were evaluated as sporadic or hereditary, tumor node metastasis (TNM) staging, single or multifocal focus, recurrence or regional or distant metastasis, progression-free survival time (PFS), and appropriate pathology tissue samples were determined as PEDF, VEGF, NF-kB, Ki-67 staining was compared. As a result of this comparison, a moderate negative correlation was found between VEGF expression level and PFS (rho = - 0,407, p = 0,019). No statistically significant correlation was found between single or multifocal groups and Ki-67 proliferation index (PI) expression levels (p = 0.070), but this is a small p value, a variable that is likely to find significant differences in studies with larger sample groups.The relationship between PEDF, VEGF, NF- kB, Ki-67 PI factors and tumor angiogenesis as reflected by microvessel density (MVD) was also investigated. To this end, we correlated the expression levels of PEDF, VEGF, NF-kB, and Ki-67 staining of suitable pathology tissue samples of the patients with the results obtained from the staining with CD 31. As a result of this comparison, no statistically significant relationship was found. Conclusions: We demonstrated and described for the first time PEDF expression patterns in MTC tumor tissues. A direct relationship between PEDF expression level and angiogenesis, angiogenetic and clinicopathological factors does not seem to exist, at least as it pertains to the group studied. Further studies are required to fully elucidate mechanisms for tumor angiogenesis and invasion in MTC.

15 April 2025 in Endocrinology Research and Practice
Verified
Journal Article
Open access
NBNergis Basmaci
Nergis Basmaci
AGAlper Gürlek
Alper Gürlek
X-linked hypophosphatemia (XLH) is a rare genetic disorder caused by mutations in the PHEX gene, and it is a primary example of a genetic cause of hypophosphatemia. The key effect of the PHEX muta tion is the overproduction of fibroblast growth factor 23 (FGF23), a known phosphatonin. Elevated FGF23 levels lead to renal phosphate wasting, reduced synthesis of 1,25(OH)2 D, and decreased para thyroid hormone levels. Chronic elevation of FGF23 is the root cause of lifelong hypophosphatemia. This ongoing phosphate deficiency leads to impaired growth, poor bone mineralization, and a variety of skeletal, dental, auditory, and cardiovascular issues, all of which negatively impact quality of life and may contribute to premature mortality. While phosphate supplementation and 1,25(OH)2 D ther apy remain foundational treatments, strategies targeting FGF23 have shown promising results and gained greater importance over the last decade. X-linked hypophosphatemia is a complex, multisys tem condition with lifelong effects, requiring a multidisciplinary approach to care. Cite this article as: Basmaci N, Gürlek A. X-linked hypophosphatemia with whole aspects. Endocrinol Res Pract. 2025;29(3):235-243.